CTT PHARMACEUTICAL HOLDINGS, INC.: 10-Q filed 2012-05-14
What CTT PHARMACEUTICAL HOLDINGS, INC. reported in its quarterly report filed 2012-05-14 (fiscal Q1 2012): 19 published measures, 40 facts as tagged in accession 0001204459-12-001085.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-05-14
- Fiscal period
- fiscal Q1 2012
- Accession
- 0001204459-12-001085 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CTT PHARMACEUTICAL HOLDINGS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 1,329,400 | USD | |
| At 2011-12-31 | 4,182,995 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 561,637 | USD | |
| At 2011-12-31 | 3,726,545 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 181,932 | USD | |
| At 2011-12-31 | 569,378 | USD | |
| At 2011-03-31 | 396,014 | USD | |
| At 2010-12-31 | 0 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -682,376 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 5,689,064 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -619,501 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -11,520 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 198,305 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 407,534 | USD | 90 |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 9,409,872 | shares | 91 |
| 2011-01-01 to 2011-03-31 | 8,885,081 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 9,482,194 | shares | 91 |
| 2011-01-01 to 2011-03-31 | 9,238,652 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -0.07 | USD/shares | 91 |
| 2011-01-01 to 2011-03-31 | 0.64 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -0.07 | USD/shares | 91 |
| 2011-01-01 to 2011-03-31 | 0.62 | USD/shares | 90 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 42,268 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 0 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -682,818 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -26,858 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 1,329,400 | USD | |
| At 2011-12-31 | 750,734 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 682,818 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 26,858 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 9,413,581 | shares | |
| At 2011-12-31 | 9,413,581 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 12,613,109 | USD | |
| At 2011-12-31 | 12,537,316 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 851,289 | USD | |
| At 2011-12-31 | -105,985 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 767,763 | USD | |
| At 2011-12-31 | 456,450 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 55,456 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 9,676 | USD | 90 |
Inspect the source
- Entity
- CTT PHARMACEUTICAL HOLDINGS, INC. / CIK 0001035422
- Captured
- 2026-09-20T05:15:10.936Z
- SEC response SHA-256
21b0a0ba4c84772224f4978cbe9507956b8d731d5fe56b447e41295eab5239b0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035422.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))